July 25, 2016 — The Centers for Medicare and Medicaid Services (CMS) announced that it expects to launch its new Overall Hospital Quality Star Rating system to report on quality of care at hospitals shortly.
July 26, 2016 — Hematology researchers at The Children’s Hospital of Philadelphia (CHOP) have developed a novel genetically engineered clotting factor that can control bleeding in animal models. If the factor proves effective in humans, it may provide a quick-acting countermeasure for surgery patients and others vulnerable to serious bleeding as a result of new blood-thinning drugs.
July 26, 2016 — The Centers for Medicare & Medicaid Services (CMS) has proposed the creation of new bundled payment models for patients who have a heart attack or undergo coronary artery bypass surgery. Several medical societies released statements on the proposed models, including the Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC). Â
Stryker Sustainability Solutions (formerly Ascent Healthcare Solutions) is recalling Angiodynamics Soft Vu Omni Flush Angiographic Catheters due to reports of separation of the tip of the catheter from the main body.
UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-based physician group in Central New Jersey, implemented UltraSPECT’s Xpress3.Cardiac solution at four of their sites.
July 22, 2016 — The Centers for Medicare & Medicaid Services (CMS) recently announced 516 awardees in 47 states, Puerto Rico, and the District of Columbia to help reduce the risks for heart attacks and strokes among millions of Medicare fee-for-service beneficiaries.
CardioKinetix Inc. announced this week that 500 patients have received the company’s Parachute Ventricular Partitioning Device for heart failure. Patients have been treated in more than 15 countries, including patients in key international markets where the device is commercially available, and patients enrolled in PARACHUTE IV, the company’s U.S. pivotal trial under investigational device exemption (IDE).
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a recent study in the Journal of the American College of Cardiology.